MAGEA3 and breast cancer: These results compared favourably with those obtained for the MAGE-A(1–4), LAGE-1, PASD-1, and NY-ESO-1 CTAs in haematological malignancies [13, 29, 40] and for CEA, HER-2/neu, and MAGE-A3 in breast cancer [41].